Method of extracting from the patient's own blood enriched platelet factors (EnPLAF) and application thereof in treatment of various medical conditions

Abstract

Disclosed is a method of extracting, from the patient's own blood, enriched platelet factors, or EnPLAF, storable supernatant, void of live blood cells, utilized for treatment of said patient's medical conditions, including but not limited to pain management, aesthetic rejuvenation, bone, muscle and soft tissue healing.

Claims

1. A method of extracting enriched platelet factors from human blood, comprising: a. providing means of extracting 10 cc of human blood from a patient, b. providing a vacutainer tube for collection of said human blood which is able to retain said blood when mixed by manually inverting the vacutainer tube or by using a mechanical centrifuge, c. mixing the human blood in said vacutainer tube by manually inverting the vacutainer tube four or five times, d. providing a mechanical centrifuge, situated in room temperature, which can rotate the vacutainer tube, containing the human blood, continuously for 20 minutes at 2000 rpm causing buildup of plasma, e. providing means of removing the plasma from the vacutainer tube, which will allow to leave in said vacutainer tube 1 cc of the created plasma f. providing means of inserting into the vacutainer tube reagent A, which will allow for insertion into the vacutainer tube 100 units of pharmaceutical-grade Thrombin, Page 15 of 18 g. mixing blood cells, platelets, plasma and the pharmaceutical-grade Thrombin in said vacutainer tube by manually inverting the tube four or five times, h. providing an incubator which can store the vacutainer tube, containing the plasma mixed with the blood cells, platelets, and pharmaceutical-grade Thrombin, for 1 hour at a temperature equivalent to 37 C., i. providing means of inserting into the vacutainer tube reagent B, which will allow for insertion into the vacutainer tube, containing the plasma mixed with the blood cells, platelets, and pharmaceutical-grade Thrombin, 2 cc of saline or ringer lactate, j. rotating the vacutainer tube, containing the plasma mixed with the blood cells, platelets, pharmaceutical-grade Thrombin and saline, in said centrifuge at room temperature continuously for 20 minutes at 2000 rpm, creating a separation of supernatant, k. extracting the supernatant from said vacutainer tube, which is enriched platelet factors, l. using said enriched platelet factors for bone healing, m. using said enriched platelet factors for muscle healing, n. using said enriched platelet factors for tissue healing, o. administering enriched platelet factors to the patient as an injection, p. administering enriched platelet factors to the patient topically as a cream base, q. administering enriched platelet factors to the patient topically as a healing patch.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) The components shown in the drawings are not to scale. In the interest of clarity, some of the components might be shown in a generalized form and could be identified utilizing commercial designations. All components, including its essential features, have been assigned reference numbers that are utilized consistently throughout the descriptive process outlined herein:

(2) FIG. 1 is an illustrative diagram showing the enriched platelet factors treatment cycle, focusing on extraction and application of the of the enriched platelet factors to a patient, in accordance with an exemplary embodiment of the present invention;

(3) FIG. 2 is a flowchart diagram illustrating the general step undertaken during the application of the enriched platelet factors treatment cycle, in accordance with an exemplary embodiment of the present invention;

(4) FIG. 3 is a flowchart diagram illustrating the logical process undertaken during the doctor's evaluation of the patient, intended to determine said patient's ability to accept the platelet factors treatment, in accordance with an exemplary embodiment of the present invention;

(5) FIG. 4 is a flowchart diagram illustrating the review of the enriched platelet factors extraction procedure, focusing on determining the existence of the necessary medical equipment for extraction of the enriched platelet factors, in accordance with an exemplary embodiment of the present invention;

(6) FIG. 5 is an illustrative diagram, listing the equipment used for extraction of the enriched platelet factors, in accordance with an exemplary embodiment of the present invention;

(7) FIG. 6 is an illustrative diagram showing the method used for extraction of the enriched platelet factors, in accordance with an exemplary embodiment of the present invention;

(8) FIG. 7 is a flowchart diagram illustrating various methods of administering to the patient, the enriched platelet factors and their applicable treatments, in accordance with an exemplary embodiment of the present invention.

DETAILED DESCRIPTION AND BEST MODE OF IMPLEMENTATION

(9) The following description references to the above-defined drawings and represents only an exemplary embodiment of the invention. It is foreseeable, and recognizable by those skilled in the art, that various modifications and/or substitutions to the invention could be implemented without departing from the scope and the character of the invention:

(10) The present invention, outlined in FIGS. 1-7, discloses a method of extracting, from the patient's own blood, enriched platelet factors (EnPLAF) 700 and application thereof in treatment 100 of said patient's medical conditions, including but not limited to pain management, bone, muscle and soft tissue healing.

(11) As shown in FIG. 1 shows the EnPLAF treatment cycle, and FIG. 2, shows the process of implementing the EnPLAF treatment 100. The treatment starts with an informational meeting 200, conducted in a controlled environment of a medical office 210, by a physician, aesthetician 230 and/or other authorized individual. The information provided during the meeting 200 may be communicated utilizing standardized information methods 220, including but not limited to verbal and visual presentations. The purpose of the meeting is to inform the potential patient about the benefits and the drawbacks of the EnPLAF treatment 100.

(12) Once the informational session 200 has been completed, the physician 230, or other authorized individual, evaluates the patient's physical condition 300 to determine his/her ability to accept the EnPLAF treatment 100 (Ref. FIGS. 1, 2 and 3). Here, the patent's general physical condition is assessed 310, followed by evaluation of the patient's ability to produce platelets 320-329. The evaluation 300 focuses directly on both the patient's relative 330 and absolute 340 treatment contraindicators.

(13) The relative 330 treatment contraindicators, assess the potential patient's ability to accept the EnPLAF treatment 100 by looking for the following conditions: 1) consistent use of NSAIDs 331 48 hours before the treatment 100; 2) injection of corticosteroid 332 at treatment site within 1 month before the treatment 100; 3) systematic use of corticosteroid 333 within 2 weeks before the treatment 100; 4) use of tobacco 334; 5) recent fever or illness 335; 6) cancer 336. The uncovered, relative 330 treatment contraindicators are meticulously analyzed by the physician 230, who will ultimately makes the final determination 350, specifying whether the patient may, or may not, receive the EnPLAF treatment 100 (Ref. FIG. 3).

(14) The absolute 340 treatment contraindicators, assess the potential patient's ability to accept the EnPLAF treatment 100 by looking for the following conditions: 1) Platelet Disfunction Syndrome 341; 2) Critical Thrombocytopenia 342; 3) Hemodynamic Instability 343; 4) Septicemia 344; 5) Infection at the Site of the Procedure 345; 6) Patient's Unwillingness to Accept the Risk of the Procedure 346. The revealed relative 330 treatment contraindicators will prevent the patient from participating in the EnPLAF treatment 100 (Ref. FIG. 3).

(15) Once the patient's ability to participate in the EnPLAF treatment 100 is confirmed, the physician (or other authorized individual) collects the patient's blood, which will be utilized to extract the enriched platelet factors (Ref. FIGS. 1 and 2). The blood may be collected from the patient by utilizing various techniques, including but not limited to available veinpunctre methods 410 (i.e. winged infusion 411, needle/syringe 412 and vacuum tube 413 methods).

(16) Next, in accordance with the method for extracting the enriched platelet factors 500 and 700, the patient's blood is placed into a heparinized vacutainer tube 501/701 (Ref. FIGS. 4, 5 and 6). Once in the tube 501/701, the blood should be well mixed by inverting the tube 4-5 times 502/702. The blood is then centrifuged in room temperature at 2000 RPM for 20 minutes 503/703. Most of the supernatant (plasma) is then taken out of the vacutainer tube, using a needle 704, and thrown out, leaving approximately 1 cc of plasma 504/705. Next, the vacutainer tube is infused with 100 units of Reagent A (pharmaceutical grade Thrombin) 505/706. Upon completion of this procedure, the blood is once again mixed manually 506/708, and is thereafter placed in an incubator, capable of maintaining the temperature of 37 C. for a period of one hour 507/708. Upon removal from the incubator, using a needle 709, the blood is infused with Reagent B, or 2 cc of saline or ringer lactate 508/710, and once again the blood is placed inside of the centrifuge that is operated in room temperature at 2000 RPM for 20 minutes 509/712. Once the centrifuge operation is completed, the process of extracting the enriched platelet factors 700 is finalized, and ready for the administrative procedures 800.

(17) As shown in FIG. 7, the formulated supernatant containing the EnPLAF 700, may be administered to a patient to treat numerous medical conditions. The methods 800 of administering the EnPLAF treatment 100, including but not limited to:

(18) 1) injection of autologous growth factors, directly into the patient's affected area (e.g. this application may be utilized for treatment of sexual dysfunctions, podiatric issues, healing associated with dental treatments, pain management, general wound healing, orthopedic problems, aesthetic issues, including breasts rejuvenation and hair restoration) 801;

(19) 2) mixing the EnPLAF 700 with a cream base, which may be utilized at-home as a non-injection alternative (e.g. this application may be utilized for treatment of aesthetic-related conditions and general wound healing) 802;

(20) 3) applying the EnPLAF 700 in the form of a wound healing patch, designed to deliver autologous growth factors directly to the problem area (e.g. this application may be utilized for treatment of aesthetic-related conditions and general wound healing) 803;

(21) 4) applying the EnPLAF 700 in the form of a topical medication with local therapeutics (e.g. this application may be utilized for treatment of aesthetic-related conditions, pain reduction, healing of minor burns and scars) 804;

(22) 5) utilizing any of the above-listed methods, to deliver autologous growth factors directly to the problem area during the preoperative and postoperative phases of surgery (e.g. this application may be utilized for treatment of aesthetic-related conditions, pain and to accelerated the healing process) 805.